Otsuka Pharmaceutical to acquire Jnana Therapeutics in deal worth over $1.1bn

The agreement includes a clinical-stage drug for the rare inherited metabolic disorder phenylketonuria

(August 1, 2024) | By Emily Kimber.

Jnana’s JNT-517 is an allosteric small molecule inhibitor of SLC6A19, a solute carrier that regulates amino acid reabsorption in the kidney, and has already been shown in a phase 1b/2 study to be effective, well-tolerated and safe.

The acquisition also includes RAPID, Jnana’s next-generation chemoproteomics platform designed to discover medicines for challenging-to-drug targets.